Penumbra Q4 2021 revenue $204M (+22% YoY); GAAP op loss $40.1M, adjusted op income $2.5M

Penumbra Inc

2021-FY EPS reported $0.14 revenue$747,590,000

Q4 revenue $204.0M (+22.2% YoY; +23.0% constant currency); US $144.5M (+23.7%).
Vascular revenue $113.6M (+30.4%); neuro revenue $90.4M (+13.3%).
GAAP operating loss $40.1M; non-GAAP op income $2.5M excluding $25.8M Sixense accelerated vesting and $15.0M Thunderbolt R&D milestone.
Full year 2021 revenue $747.6M (+33.4%); non-GAAP op income $40.1M vs prior year loss of $22.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.